Sydney, Australia, 15 November, 2017: The Directors of Biotron Limited (ASX: BIT) are pleasedto advise that in recently completed preclinical studies several of the Company’s compounds havedemonstrated significant anti-viral activity against hepatitis B (HBV). The studies were completed inthe USA in cell culture models that are considered ‘industry standard’ and are well recognised bypotential pharma and biotech partners.
BIT Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)